Saladax is developing a pipeline of in vitro diagnostic assays that enable personalized treatment of patients with the goal of improved treatment efficacy and/or reduced toxicity. The Company ™s initial focus is in the oncology field, with the development of its line of MYCARE?„? assays that measure chemotherapy drug levels in plasma using proprietary monoclonal antibodies bound to nanoparticles. The first test developed by Saladax that is available to patients is OnDose, which is a test Saladax licensed to Myriad Genetics in 2008. OnDose enables oncologists to optimize infusional 5-FU therapy on an individual basis. OnDose provides the data for pharmacokinetically-guided dose adjustments of infusional 5-FU to help optimize dosing for patients with colorectal cancer. Using the current standard of care, 5-FU dosing is based on an assessment of Body Surface Area. Many studies have demonstrated that there is a high inter-patient variability in the blood level of 5-FU when dosed by Body Surface Area, leading to sub-optimal treatment efficacy or undue toxicity.

Source Saladax Biomedical, Inc.